Dysregulation of the fibroblast growth factor system in major depression
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
In this report we describe findings that imply dysregulation of several fibroblast growth factor (FGF) system transcripts in frontal cortical regions of brains from human subjects with major depressive disorder (MDD). This altered gene expression was discovered by microarray analysis of frontal cortical tissue from MDD, bipolar, and nonpsychiatric control subjects and was verified by quantitative real-time PCR analysis and, importantly, in a separate cohort of MDD subjects. Furthermore, we show, through a separate analysis of specific serotonin reuptake inhibitor (SSRI)-treated and non-SSRI-treated MDD subjects that the observed changes in expression of FGF transcripts are not secondary to drug treatment. Rather, changes in specific FGF transcripts are attenuated by SSRIs and may thus be partially responsible for the mechanism of action of these drugs. We also make available the gene-expression profile of all of the other growth factors and growth factor receptors detected in these postmortem samples.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Post-mortem brain analysis in humans revealed a lower expression of FGF1 and FGF2 in the dorsolateral PFC and the ACC of patients with MDD (Evans et al. 2004).”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Evans et al. 2004
Citations
Cites
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene
Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., et al. (2003) · Science · doi:10.1126/science.1083968 · Cited by 8,120
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma
Gilbertson, M. W., Shenton, M. E., Ciszewski, A., Kasai, K., Lasko, N. B., Orr, S. P., & Pitman, R. K. (2002) · Nature Neuroscience · doi:10.1038/nn958 · Cited by 1,635
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151
Lee, J., Duan, W., & Mattson, M. P. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01085.x · Cited by 975
Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia
Weickert, C. S., Hyde, T. M., Lipska, B. K., Herman, M. M., Weinberger, D. R., & Kleinman, J. E. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001308 · Cited by 532
Tomita, H., Vawter, M. P., Walsh, D. M., Evans, S. J., Choudary, P. V., Li, J., Overman, K. M., Atz, M. E., Myers, R. M., Jones, E. G., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.10.013 · Cited by 331
Self-citationThe neuropathology of primary mood disorder
Harrison, P. J. (2002) · Brain · doi:10.1093/brain/awf149 · Cited by 322
López-Figueroa, A. L., Norton, C. S., López-Figueroa, M. O., Armellini-Dodel, D., Burke, S., Akil, H., López, J. F., & Watson, S. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.017 · Cited by 296
Self-citation
Research works printed but not linked: 4
- Watson S. J. Patel P. Burke S. Herman J. Shaffer M. & Kwak S. (1988) in Short Course 1 Syllabus ed. Sunderman A. (Soc. Neurosci. Washington DC) pp. 4-29.
- Neal, C. R., Jr., Akil, H. & Watson, S. J., Jr. (2001) J. Chem. Neuroanat. 22, 219-249.11719021
- Parikh, V., Evans, D. R., Khan, M. M. & Mahadik, S. P. (2003) Schizophr. Res. 60, 117-123.12591576
- Dono, R. (2003) Am. J. Physiol. 284, R867-R881.
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
“Interestingly, patients suffering from major depressive disorder have deregulated FGF transcript levels that are restored by serotonin reuptake inhibitor”
Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment
Warner‐Schmidt, J. L., & Duman, R. S. (2006) · Hippocampus · doi:10.1002/hipo.20156 · Cited by 787
“A recent report also demonstrates that the FGF2 system is altered in postmortem tissue of depressed subjects (Evans et al., 2004).”
BackgroundSex-specific transcriptional signatures in human depression
Labonté, B., Engmann, O., Purushothaman, I., Menard, C., Wang, J., Tan, C., Scarpa, J. R., Moy, G., Loh, Y.-H. E., Cahill, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4386 · Cited by 748
Revisiting the Stress Concept: Implications for Affective Disorders
McEwen, B. S., & Akil, H. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0733-19.2019 · Cited by 686
“For example, the FGF family was discovered to be dysregulated in major depression (Evans et al., 2004; Aurbach et al., 2015).”
BackgroundSelf-citationRole of neurotrophic factors in depression
CASTREN, E., VOIKAR, V, & RANTAMAKI, T. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.009 · Cited by 667
“Dysregulation of several members of the FGF family and their receptors has been found to occur in brains of patients with major depressive disorder [26], and FGFs are regulated by antidepressant drugs [27].”
BackgroundChoudary, P. V., Molnar, M., Evans, S. J., Tomita, H., Li, J. Z., Vawter, M. P., Myers, R. M., Bunney, W. E., Akil, H., Watson, S. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507901102 · Cited by 652
Self-citationSchmidt, H. D., & Duman, R. S. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282ee2aa8 · Cited by 648
“Altered expression of FGF-2 and FGF receptors is observed in adult patients with MDD and these changes are reversed by antidepressant treatment (Evans et al., 2004; Gaughran et al., 2006).”
BackgroundGliogenesis and Glial Pathology in Depression
Rajkowska, G., & Miguel-Hidalgo, J. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780619326 · Cited by 610
Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Rajkowska, G., & Stockmeier, C. (2013) · Current Drug Targets · doi:10.2174/13894501113149990156 · Cited by 603
“Conversely, repeated treatment with antidepressant medication up-regulates expression of BDNF and FGF2 factors in humans and rodents [183, 191-193].”
BackgroundPsychiatric genetics: progress amid controversy
Burmeister, M., McInnis, M. G., & Zöllner, S. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2381 · Cited by 525
Shelton, R. C., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D. A., & Mirnics, K. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.52 · Cited by 511
Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 474
“FGF-2, FGF receptors, and the GDNF receptor are altered by antidepressant treatment (Chen et al, 2001a; Evans et al, 2004; Gaughran et al, 2006).”
BackgroundBonfili, L., Cecarini, V., Berardi, S., Scarpona, S., Suchodolski, J. S., Nasuti, C., Fiorini, D., Boarelli, M. C., Rossi, G., & Eleuteri, A. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-02587-2 · Cited by 453
Treatment resistant depression: A multi-scale, systems biology approach
Akil, H., Gordon, J., Hen, R., Javitch, J., Mayberg, H., McEwen, B., Meaney, M. J., & Nestler, E. J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.019 · Cited by 442
“…technology, with recent efforts moving to RNA-sequencing (RNA-seq) (e.g., Bernard et al., 2011; Choudary et al., 2005; Duric et al., 2013; Evans et al., 2004; Gaiteri and Sibille, 2011; Iwamoto et al., 2004; Kang et al., 2007; Klempan et al., 2009; Labonté et al., 2017; Lalovic et al.,…”
BackgroundSelf-citationBernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Akil, H., & Watson, S. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.44 · Cited by 372
“…results implicate MDD-specific dysfunctions in glutamate and growth factor signaling with special emphasis on altered astroglial transcripts, which is in strong agreement with previous studies from dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (AnCg) of MDD patients 20 , 21 .”
InfluentialSelf-citationANISMAN, H., MERALI, Z., & HAYLEY, S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.004 · Cited by 337
“The present review focuses on the potential contribution of BDNF in depression, but this should not be taken to exclude a role for other growth factors, including FGF1 and FGF2, that are influenced by stressors and have also been implicated in the evolution of depressive states (Evans et al., 2004; Newton and Duman, 2…”
Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Neuronal plasticity: A link between stress and mood disorders
Calabrese, F., Molteni, R., Racagni, G., & Riva, M. A. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.014 · Cited by 301
“In particular the expression of FGF-1, FGF-2, and their receptors FGFR2 and FGFR3, is decreased throughout the limbic system, whereas the levels of FGF-9 and FGF- 12 appear to be up-regulated (Evans et al., 2004).”
BackgroundInfluentialCellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder
Zarate, C. A., Singh, J., & Manji, H. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.021 · Cited by 274
“…of several fibroblast growth factor (FGF) system transcripts in frontal cortical regions of brains from human subjects with major depressive disorder suggests that this growth factor family may also represent an important target for the development of novel therapeutics (Evans et al 2004).”
BackgroundConsensus paper of the WFSBP Task Force on Biological Markers: Biological Markers in Depression
Mössner, R., Mikova, O., Koutsilieri, E., Saoud, M., Ehlis, A.-C., Müller, N., Fallgatter, A. J., & Riederer, P. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701263303 · Cited by 254
“The most significant differences were in levels of mRNA for one of the FGFs, called FGF1, and for the two receptors, FGFR2 and FGFR3 (Evans et al. 2004).”
BackgroundInfluentialTabarés-Seisdedos, R., & Rubenstein, J. L. R. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.2 · Cited by 244
“Two recent postmortem analyses, showed a reduction, on the one hand, of FGF members ( FGF1, FGF2, FGFR2 and FGFR3 ) in the frontal cortex of major depressed subjects compared with control and bipolar subject”
BackgroundFrom Cradle to Grave: The Multiple Roles of Fibroblast Growth Factors in Neural Development
Guillemot, F., & Zimmer, C. (2011) · Neuron · doi:10.1016/j.neuron.2011.08.002 · Cited by 235
Novel Drugs and Therapeutic Targets for Severe Mood Disorders
Mathew, S. J., Manji, H. K., & Charney, D. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301652 · Cited by 223
Stress during development: Impact on neuroplasticity and relevance to psychopathology
Fumagalli, F., Molteni, R., Racagni, G., & Riva, M. A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.01.002 · Cited by 220
Belzeaux, R., Bergon, A., Jeanjean, V, Loriod, B., Formisano-Tréziny, C., Verrier, L., Loundou, A., Baumstarck-Barrau, K., Boyer, L., Gall, V, et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.112 · Cited by 219
Hypothalamic and other connections with dorsal CA2 area of the mouse hippocampus
Cui, Z., Gerfen, C. R., & Young, W. S. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23263 · Cited by 214
“Fibroblast growth factor 2 (FGF2), enriched in the CA2 (Turner et al., 2011), is expressed at lower levels in the hippocampus of patients with major depressive disorder (Evans et al., 2004; Gaughran et al., 2006).”
BackgroundIdentifying blood biomarkers for mood disorders using convergent functional genomics
Le-Niculescu, H., Kurian, S. M., Yehyawi, N., Dike, C., Patel, S. D., Edenberg, H. J., Tsuang, M. T., Salomon, D. R., Nurnberger, J. I., & Niculescu, A. B. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.11 · Cited by 211
Duman, R. S. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/rsduman · Cited by 210
Conti, B., Maier, R., Barr, A. M., Morale, M. C., Lu, X., Sanna, P. P., Bilbe, G., Hoyer, D., & Bartfai, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001897 · Cited by 204
Le‐Niculescu, H., Patel, S. D., Bhat, M., Kuczenski, R., Faraone, S. V., Tsuang, M. T., McMahon, F. J., Schork, N. J., Nurnberger, J. I., & Niculescu, A. B. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30887 · Cited by 201
Inventing new medicines: The FGF21 story
Kharitonenkov, A., & Adams, A. C. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.003 · Cited by 198
“Given that the development of FGF21 advanced hand-in-hand with rapidly evolving scientific research around this target, we have also attempted to describe our view of recent developments regarding the mechanistic understanding of FGF21 biology.”
BackgroundPatterns of gene expression in the limbic system of suicides with and without major depression
Sequeira, A., Klempan, T., Canetti, L., ffrench-Mullen, J., Benkelfat, C., Rouleau, G. A., & Turecki, G. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001969 · Cited by 197
Vawter, M. P., Tomita, H., Meng, F., Bolstad, B., Li, J., Evans, S., Choudary, P., Atz, M., Shao, L., Neal, C., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001830 · Cited by 188
Self-citationGenetic factors influencing alcohol dependence
Mayfield, R. D., Harris, R. A., & Schuckit, M. A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.88 · Cited by 186
“In addition, psychiatric disorders such as schizophrenia (Mirnics et al., 2000, 2001; Pongrac et al., 2004), major depression (Evans et al., 2004), bipolar disorder (Iwamoto et al., 2004b) and autism (Purcell et al., 2001) have been studied successfully.”
BackgroundKiraly, D. D., Horn, S. R., Van Dam, N. T., Costi, S., Schwartz, J., Kim-Schulze, S., Patel, M., Hodes, G. E., Russo, S. J., Merad, M., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.31 · Cited by 186
Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder
Gaughran, F., Payne, J., Sedgwick, P. M., Cotter, D., & Berry, M. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.04.008 · Cited by 178
Making room for oxytocin in understanding depression
McQuaid, R. J., McInnis, O. A., Abizaid, A., & Anisman, H. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.07.005 · Cited by 174
Tochigi, M., Iwamoto, K., Bundo, M., Sasaki, T., Kato, N., & Kato, T. (2007) · Neuroscience Research · doi:10.1016/j.neures.2007.10.010 · Cited by 172
“Evans et al. (2004) observed dysregulation of the fibroblast growth factor (FGF) system in subjects with major depression.”
BackgroundAntidepressant Effects of Fibroblast Growth Factor-2 in Behavioral and Cellular Models of Depression
Elsayed, M., Banasr, M., Duric, V., Fournier, N. M., Licznerski, P., & Duman, R. S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.003 · Cited by 169
“Levels of FGF2 and its receptors are down regulated in the PFC and other limbic brain regions in depressed subjects (13–15), and antidepressant treatment opposes these effects and up regulates FGF2 in humans (13) and rodents in preclinical models (16, 17).”
BackgroundNeurobiology of Major Depressive Disorder
Villanueva, R. (2013) · Neural Plasticity · doi:10.1155/2013/873278 · Cited by 125
“in the adult brain and become downregulated in individuals suffering from MDD [88].”
Hercher, C., Turecki, G., & Mechawar, N. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.01.006 · Cited by 163
“This view has received further support from recent studies showing a dysregulation in the cortical fibroblast growth factor (FGF) system in MDD (Evans et al., 2004) and decreases in brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) concentrations in the brains of suicide victims (Dwivedi et al.”
ResultFox, A. S., & Kalin, N. H. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14040449 · Cited by 161
“Although the work above specifically implicates NTRK3, FGF2, and other plasticity-related targets in relation to anxiety, we believe that these results reflect involvement of broader neuroplasticityrelated systems.”
InfluentialThe Fibroblast Growth Factor Family: Neuromodulation of Affective Behavior
Turner, C. A., Watson, S. J., & Akil, H. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.037 · Cited by 160
Self-citationErnst, C., Mechawar, N., & Turecki, G. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.09.001 · Cited by 158
“Choudary et al. (2005) used tissue from BA9 and anterior cingulate cortex from 7 controls, 9 MDD subjects and 6 BPD to generate microarray data—these subjects appear to be identical to those subjects used in the paper by Evans et al. (2004).”
A New Role for FGF2 as an Endogenous Inhibitor of Anxiety
Perez, J. A., Clinton, S. M., Turner, C. A., Watson, S. J., & Akil, H. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4829-08.2009 · Cited by 145
“Our own studies have revealed that the fibroblast growth factor (FGF) system was the molecular ensemble most significantly altered in depressed individuals, across several cortical and subcortical regions (Evans et al., 2004; Akil et al., 2008).”
BackgroundSelf-citationTarget Identification for CNS Diseases by Transcriptional Profiling
Altar, C. A., Vawter, M. P., & Ginsberg, S. D. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.172 · Cited by 142
Self-citationMolecular biomarkers of depression
Gururajan, A., Clarke, G. A., Dinan, T. G., & Cryan, J. F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.011 · Cited by 153
Martiny, K., Lunde, M., & Bech, P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.02.017 · Cited by 149
Flagel, S. B., Waselus, M., Clinton, S. M., Watson, S. J., & Akil, H. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.033 · Cited by 126
“Our interest in the fibroblast growth factor (FGF) family emerged from a study examining alterations in genome-wide expression profiles in the brains of patients suffering from major depressive disorder (MDD) (Evans et al., 2004).”
Self-citationCritical Appraisal of DNA Microarrays in Psychiatric Genomics
Mirnics, K., Levitt, P. R., & Lewis, D. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.003 · Cited by 146
Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness
Hökfelt, T., Barde, S., Xu, Z.-Q. D., Kuteeva, E., Rüegg, J., Le Maitre, E., Risling, M., Kehr, J., Ihnatko, R., Theodorsson, E., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00106 · Cited by 139
Mesenchymal stem cells increase hippocampal neurogenesis and counteract depressive-like behavior
Tfilin, M., Sudai, E., Merenlender, A., Gispan, I. H., Yadid, G., & Turgeman, G. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.110 · Cited by 139
Borroto‐Escuela, D. O., Romero‐Fernandez, W., Mudò, G., Pérez‐Alea, M., Ciruela, F., Tarakanov, A. O., Narváez, M., Liberto, V. D., Agnati, L. F., Belluardo, N., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.012 · Cited by 138
“In fact, fibroblast growth actor 2 (FGF2) messenger RNA (mRNA) levels in the hippocampus re reduced in major depression (8,9) and this region appears to how an especially strong atrophy (10).”
BackgroundTakebayashi, M., Hisaoka, K., Nishida, A., Tsuchioka, M., Miyoshi, I., Kozuru, T., Hikasa, S., Okamoto, Y., Shinno, H., Morinobu, S., et al. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006085 · Cited by 132
“In correspondence with these studies, recent findings showed that brain-derived neurotrophic factor (BDNF), neurotrophin-3 and fibroblast growth factor (FGF) systems, which are potent regulators for neuronal plasticity, survival and development, are altered in different samples such as post-mortem brain, cerebrospinal…”
BackgroundResultInfluentialNeuroplasticity, Psychosocial Genomics, and the Biopsychosocial Paradigm in the 21st Century
Garland, E. L., & Howard, M. O. (2009) · Health & Social Work · doi:10.1093/hsw/34.3.191 · Cited by 107
Inflammatory Factors Contribute to Depression and Its Comorbid Conditions
Anisman, H., & Hayley, S. (2012) · Science Signaling · doi:10.1126/scisignal.2003579 · Cited by 117
Fibroblast Growth Factor Signalling in the Diseased Nervous System
Klimaschewski, L., & Claus, P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02367-0 · Cited by 120
The Fibroblast Growth Factor System and Mood Disorders
Turner, C. A., Akil, H., Watson, S. J., & Evans, S. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.026 · Cited by 131
Self-citationStructure and function of dendritic spines within the hippocampus
Halbach, O. V. B. U. (2009) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2009.08.006 · Cited by 128
Gene Expression Profiling in Postmortem Prefrontal Cortex of Major Depressive Disorder
Kang, H. J., Adams, D. H., Simen, A., Simen, B. B., Rajkowska, G., Stockmeier, C. A., Overholser, J. C., Meltzer, H. Y., Jurjus, G. J., Konick, L. C., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4083-07.2007 · Cited by 119
“The results of the current study confirm the findings of a recent postmortem study (Evans et al., 2004), demonstrating decreased expression of FGFR3 in the DLPFC.”
BackgroundResultAntidepressant-like effects of intracerebroventricular FGF2 in rats
Turner, C. A., Gula, E. L., Taylor, L. P., Watson, S. J., & Akil, H. (2008) · Brain Research · doi:10.1016/j.brainres.2008.05.088 · Cited by 125
“More recent studies have also extended these findings to the hippocampus (Evans et al., 2004b), pointing to an overall ‘net decrease’ in the tone of the FGF system in MDD.”
BackgroundSelf-citationInterplay between pro-inflammatory cytokines and growth factors in depressive illnesses
Audet, M.-C., & Anisman, H. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00068 · Cited by 104
“Limited FGF-2 down-regulation was apparent in those patients that had been treated with antidepressants (Evans et al., 2004), a finding also seen in mice in which antidepressants increased FGF-2 expression and immunoreactivity in hippocampus and PFC (Gómez-Pinilla et al.”
BackgroundEvidence for alterations of the glial syncytial function in major depressive disorder
Medina, A., Watson, S. J., Bunney, W., Myers, R. M., Schatzberg, A., Barchas, J., Akil, H., & Thompson, R. C. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.010 · Cited by 108
“However, there is growing evidence in the literature of a substantial role of glia cells in the pathogenesis of MDD (Evans et al., 2004; Choudary et al., 2005; Bernard et al., 2011; Ordway et al., 2012; Medina et al., 2013a).”
BackgroundSelf-citationLe‐Niculescu, H., McFarland, M. J., Ogden, C. A., Balaraman, Y., Patel, S., Tan, J., Rodd, Z. A., Paulus, M., Geyer, M. A., Edenberg, H. J., et al. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30707 · Cited by 111
“Both the insulin growth factor system [Bezchlibnyk et al., 2007] and the fibroblast growth factor system [Evans et al., 2004] have been implicated in the pathogenesis of mood disorders [Niculescu, 2005].”
BackgroundModeling depression: social dominance–submission gene expression patterns in rat neocortex
Kroes, R. A., Panksepp, J., Burgdorf, J. S., Otto, N. J., & Moskal, J. R. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.08.076 · Cited by 111
Stead, J. D. H., Neal, C., Meng, F., Wang, Y., Evans, S., Vazquez, D. M., Watson, S. J., & Akil, H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2755-05.2006 · Cited by 98
“…a broad unbiased survey in human postmortem tissue showed that the most striking change in major depression is in growth factor gene expression (Evans et al., 2004), consistent with candidate studies of specific growth factors (Dwivedi et al., 2003) and reinforcing the view that changes in…”
BackgroundSelf-citationMamdani, F., Rollins, B., Morgan, L., Myers, R. M., Barchas, J. D., Schatzberg, A. F., Watson, S. J., Akil, H., Potkin, S. G., Bunney, W. E., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.134 · Cited by 90
Self-citationBachis, A., Mallei, A., Cruz, M. I., Wellstein, A., & Mocchetti, I. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.014 · Cited by 96
“FGF2 was selected for a number of reasons, chief among them the fact that FGF2 expression decreases in the hippocampus and frontal cortex of depressed patients (Evans et al., 2004; Gaughran et al., 2006).”
Hisaoka, K., Takebayashi, M., Okada‐Tsuchioka, M., Maeda, N., Nakata, Y., & Yamawaki, S. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.116558 · Cited by 105
“Recent findings showed that several neurotrophic factors such as BDNF, neurotrophin-3, FGF, and GDNF are altered in post-mortem brain, cerebrospinal fluid, or blood from patients with mood disorders (Hock et al., 2000; Shimizu et al., 2003; Evans et al., 2004; Takebayashi et al., 2006).”
BackgroundThe intracrine hypothesis: An update
Ré, R. N., & Cook, J. L. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2005.09.012 · Cited by 105
Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Bell, C., Nos, L., Fried, P., Pearce, D. A., Singh, S., Siderovski, D. P., Willard, F. S., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301002 · Cited by 104
“Additionally, members of the FGF gene family have been known to be altered in depression (Evans et al, 2004).”
BackgroundTurner, C. A., Clinton, S. M., Thompson, R. C., Watson, S. J., & Akil, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103732108 · Cited by 92
“(D) FGF2 did not alter the latency to enter the light in bLR rats (two-way ANOVA: group, F(1,46) = 29.”
BackgroundMethodSelf-citationLarge-Scale Transcriptomics Studies Provide Insight Into Sex Differences in Depression
Seney, M. L., Glausier, J., & Sibille, E. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.025 · Cited by 95
Yi, Z., Li, Z., Yu, S., Yuan, C., Hong, W., Wang, Z., Cui, J., Shi, T., & Fang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031283 · Cited by 94
The Neuroplastin adhesion molecules: key regulators of neuronal plasticity and synaptic function
Beesley, P. W., Herrera‐Molina, R., Smalla, K., & Seidenbecher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12816 · Cited by 88
Dean, B. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001410 · Cited by 88
“These have suggested that changes in pathways involved in the fibroblast growth-factor system (Evans et al. 2004), oligodendrocytes (Aston et al.”
BackgroundFrom synapse to nucleus: Novel targets for treating depression
Covington, H. E., Vialou, V., & Nestler, E. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.004 · Cited by 98
“Additional neurotrophic factors, such as VEGF, FGF, and VGF (non-acronymic) have been implicated in the etiology and treatment of depression (Tsai et al., 2009; Evans et al., 2004; Warner-Schmidt and Duman, 2007).”
BackgroundSasabayashi, D., Takahashi, T., Takayanagi, Y., & Suzuki, M. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01297-8 · Cited by 98
Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients
Zhang, X., Zhang, Z., Xie, C., Xi, G., Zhou, H., Zhang, Y., & Sha, W. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.01.004 · Cited by 96
“, systems are altered in various tissues including post-mortem brain, cerebrospinal fluid, and blood from patients with mood disorders (Hock et al., 2000; Evans et al., 2004; KauerSant'Anna et al., 2009).”
BackgroundStevens (2010) · Frontiers in Neuroscience · doi:10.3389/fnins.2010.00059 · Cited by 90
Gene Expression Profiling in Schizophrenia and Related Mental Disorders
Iwamoto, K., & Kato, T. (2006) · The Neuroscientist · doi:10.1177/1073858406287536 · Cited by 86
Stress-induced changes in primate prefrontal profiles of gene expression
Karssen, A. M., Her, S., Li, J. Z., Patel, P. D., Meng, F., Bunney, W. E., Jones, E. G., Watson, S. J., Akil, H., Myers, R., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002095 · Cited by 94
Self-citationCorrelation of transcriptome profile with electrical activity in temporal lobe epilepsy
Arion, D., Sabatini, M., Unger, T., Pastor, J., Alonso-Nanclares, L., Ballesteros-Yáñez, I., García Sola, R., Muñoz, A., Mirnics, K., & DeFelipe, J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.012 · Cited by 86
“Recently, microarrays have been successfully used to examine gene expression differences in the post-mortem human brain (Ginsberg et al., 1999; Colantuoni et al., 2001; Hakak et al., 2001; Colangelo et al., 2002; Hemby et al., 2002; Blalock et al., 2004; Evans et al., 2004).”
BackgroundGene Expression Studies in Major Depression
Mehta, D., Menke, A., & Binder, E. B. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0100-3 · Cited by 87
Kajitani, N., Hisaoka-Nakashima, K., Morioka, N., Okada-Tsuchioka, M., Kaneko, M., Kasai, M., Shibasaki, C., Nakata, Y., & Takebayashi, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051197 · Cited by 85
“Indeed, the expression of FGF-2 is downregulated in postmortem brains of depressed patients [5], and increased by antidepressants in rat several brain regions [10,49].”
BackgroundStevens, H. E., Smith, K. M., Maragnoli, M. E., Fagel, D., Borok, E., Shanabrough, M., Horvath, T. L., & Vaccarino, F. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5837-09.2010 · Cited by 73
“Our findings provide a rationale for variations in Fgf gene transcripts that have been discovered in affective disorders (Evans et al., 2004; Gaughran et al., 2006) and suggest a cellular mechanism that may be involved in psychiatric illnesses.”
BackgroundG protein-linked signaling pathways in bipolar and major depressive disorders
Tomita, H., Ziegler, M. E., Kim, H. B., Evans, S. J., Choudary, P. V., Li, J. Z., Meng, F., Dai, M., Myers, R. M., Neal, C. R., et al. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00297 · Cited by 81
“These genes were analyzed in a mixed-model ANOVA utilizing Partek Pro 6.0 (Partek, MO) for the main effect of the diagnostic classification (BPD, MDD, control) and for sex (Evans et al., 2004).”
BackgroundMethodInfluentialSelf-citationMurphy‐Royal, C., Gordon, G. R., & Bains, J. S. (2019) · Glia · doi:10.1002/glia.23610 · Cited by 78
“There appears to be an overall consensus that treating astrocytes with SSRIs, such as fluoxetine, leads to increased expression of gap-junction channel proteins in cultures (Jeanson et al., 2015; Mostafavi et al., 2014) as well as in vivo with chronic fluoxetine treatment (Fatemi et al., 2008).”
InfluentialBland, S. T., Tamlyn, J. P., Barrientos, R. M., Greenwood, B. N., Watkins, L. R., Campeau, S., Day, H. E. W., & Maier, S. F. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.026 · Cited by 88
Takebayashi, M., Hashimoto, R., Hisaoka, K., Okada‐Tsuchioka, M., & Kunugi, H. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0452-1 · Cited by 89
“Further, postmortem and animal studies have suggested that antidepressant treatment could induce FGF-2 production in the brain (Evans et al. 2004; Bachis et al. 2008).”
Duric, V., & Duman, R. S. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1020-7 · Cited by 79
“This is in contrast to decreased mRNA levels of FGF2 and its receptor, FGFR1, found in the hippocampus of depressed human subjects [66, 105] and animals exposed to social defeat stress [106].”
Azevedo, J. A., Carter, B. S., Meng, F., Turner, D. L., Dai, M., Schatzberg, A. F., Barchas, J. D., Jones, E. G., Bunney, W. E., Myers, R. M., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.012 · Cited by 79
“Further work has also established alterations in various systems within AnCg in MDD and BP disorders, including dysregulation in the fibroblast growth factor (FGF) system and clock genes (Bunney et al., 2015, Cheng et al., 2007, Evans et al., 2004).”
Self-citationHagenauer, M. H., Schulmann, A., Li, J. Z., Vawter, M. P., Walsh, D. M. A., Thompson, R. C., Turner, C. A., Bunney, W. E., Myers, R., Barchas, J. D., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200003 · Cited by 87
Self-citationFibroblast Growth Factors in Schizophrenia
van Scheltinga, A. F. T., Bakker, S. C., & Kahn, R. S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp033 · Cited by 83
“postmortem study, depressed subjects treated with selective serotonine reuptake inhibitors (SSRIs) showed less decrease in FGFR2 and FGFR3 mRNA expression than depressed subjects not using SSRIs.(60)”
BackgroundDysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders
Turner, C. A., Eren‐Koçak, E., Inui, E. G., Watson, S. J., & Akil, H. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.003 · Cited by 82
“Our own interest in the role of FGFs in affective disorders began over 10 years ago based on observations in human post-mortem samples [6].”
BackgroundInfluentialSelf-citationA Model for the Involvement of Neural Cell Adhesion Molecules in Stress-Related Mood Disorders
Sandi, C., & Bisaz, R. (2007) · Neuroendocrinology · doi:10.1159/000101535 · Cited by 75
“The importance of this growth factor and its receptors in depression has been recently supported by a postmortem gene profiling study showing a profound dysregulation of this family of molecules in depressed patients, which was markedly attenuated in those patients that had received antidepressant treatment [”
ResultElevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder
Liu, X., Zhang, T., Shen, H., Hong, B., Chen, Z., Peng, D., Wu, Y., Wen, H., Lin, Z., Fang, Y., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.03.042 · Cited by 83
“And the dysfunction of neurotrophic/growth factor systems might be critically involved in the pathophysiology and treatment of mood disorders (Evans et al., 2004; Hashimoto et al., 2004; WarnerSchmidt and Duman, 2007).”
BackgroundInfluentialBoda, E. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14621 · Cited by 80
“The peer review history for this article is available at https ://publo ns.com/publo n/10.1111/ejn.14621 Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AP, action potential; BD, bipolar disorder; BDNF, brain-derived neurotrophic factor; CAT, catalase; DBS, deep brain stimulation; DSM-5, Dia…”
Influential
Metadata
- Authors
- Evans, S. J., Choudary, P. V., Neal, C. R., Li, J. Z., Vawter, M. P., Tomita, H., Lopez, J. F., Thompson, R. C., Meng, F., Stead, J. D., Walsh, D. M., Myers, R. M., Bunney, W. E., Watson, S. J., Jones, E. G., & Akil, H.
- Affiliations
- University of California, Irvine (US)
- Department of Psychiatry and Mental Health Research Institute, University of Michigan, Ann Arbor, MI 48109; Human Genome Center, Stanford University, Palo Alto, CA 94304; Center for Neuroscience, University of California, Davis, CA 95616; and Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92697
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-10-13
- Volume
- 101
- Issue
- 43
- Pages
- 15506-15511
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC523463
- OpenAlex
- W2150092716
- Cited by
- 424
- References
- 38
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 20 · 2023: 15 · 2022: 19 · 2021: 21 · 2020: 10 · 2019: 22 · 2018: 20 · 2017: 26 · 2016: 15 · 2015: 23 · 2014: 15 · 2013: 20 · 2012: 20
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Michigan
- National Institutes of Health
- University of California, Davis
- University of California, Irvine
- National Institute of Mental Health (P50MH060398, #L99MH60398)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, gene expression dysregulation, frontal cortex, bipolar disorder, serotonin reuptake inhibitors, antidepressant mechanism, growth factor receptors, postmortem brain
- MeSH terms
- Adult, Aged, Aged, 80 and over, Major Depressive Disorder, Female, Fibroblast Growth Factors, Humans, Male, Middle Aged, Polymerase Chain Reaction, Selective Serotonin Reuptake Inhibitors, In Situ Hybridization, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.